米非司酮治疗绝经过渡期子宫腺肌病临床观察

The Mifepristone's Clinical Application in Adenomyosis of Uterus During the Peri-menopausal Perod

目的探讨米非司酮在绝经过渡期子宫腺肌病的临床应用,寻求有效、并发症少、患者易于接受的方法,提高生活质量。方法对64例绝经过渡期子宫腺肌病要求保留子宫患者,口服米非司酮(12.5mg,1日1次),连服3～6个月,观察绝经的时间、血色素、月经量、痛经程度及子宫体积的变化。结果患者服药期间13例闭经,42例月经量明显减少,9例停药后恢复如治疗前;所有痛经者服药期间症状均有所减轻或消失;子宫肌层及病灶内血流量较用药前明显减少。结论米非司酮用于绝经过渡期子宫腺肌病能够有效诱导闭经,减轻痛经,减少月经量,疗效显著,安全性好,患者接受程度高。

OBJECTIVE To investigate the mifepristone＇s clinical application in adenomyosis of uterus during the peri-menopausal period and seek for effective, less-complicational, acceptable ways to improve the quality of life. METHODS 64 cases were studied retrospectively of patients who suffered from adenomyosis of uterus during the peri-menopausal period and requested to retain uterus. We observed the menopause time hemachrome, menstrual blood volume, menorrhalgia level and the change of uterus volume. RESULTS 13 patients＇menses ceased during taking the mifepristone, 42 patients had an outstanding decrease in the menstrual blood volume, and 9 patients recovered to their prior-treatment states after ceasing taking mifepristone, all the symptoms of patients with menorrhalgia had reduced or vanished during the period of taking mifepristone; the blood volume of the uterus muscular layer and focus of the diseases was less than that-before taking medicine. CONCLUSION Mifepristone can be good for inducing to cease menstruation, relieve the pains, reduce the menstrual blood volume when being applied for adenomyosis of uterus during the peri-menopausal period.It is remarkable in the therapeutic effects, excellent in security and therefore apt to being accepted by patients.